Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
The Fourth People´s Hospital of Linyi, Linyi, Shandong, China.
J Biol Regul Homeost Agents. 2018 Sep-Oct;32(5):1217-1223.
Myasthenia gravis (MG) is an autoimmune disease characterized by fatigue and muscle weakness. Artemisinin and its derivatives were reported to be experimentally used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and experimental allergic encephalomyelitis (EAE). Here, we tested the effects of artemisinin on experimental autoimmune myasthenia gravis (EAMG). Our data confirmed that artemisinin markedly ameliorated the symptoms of EAMG rats. There was a decreased level of tumor necrosis factor-α (TNF-α) and IL-17+ cells in mononuclear cells (MNCs), and an increased level of transforming growth factor-β1 (TGF-β1) and Treg cells in MNCs. These findings indicate that artemisinin may be a new choice for MG treatment.
重症肌无力（MG）是一种以疲劳和肌肉无力为特征的自身免疫性疾病。青蒿素及其衍生物被报道在实验中用于治疗自身免疫性疾病，如系统性红斑狼疮（SLE）和实验性过敏性脑脊髓炎（EAE）。在这里，我们测试了青蒿素对实验性自身免疫性重症肌无力（EAMG）的影响。我们的数据证实，青蒿素显著改善了 EAMG 大鼠的症状。在单核细胞（MNC）中，肿瘤坏死因子-α（TNF-α）和 IL-17+细胞的水平降低，而转化生长因子-β1（TGF-β1）和 Treg 细胞的水平升高。这些发现表明青蒿素可能是治疗 MG 的一种新选择。
